Norfloxacine efficacy in acute cystitis in the region with 10% resistance of E.coli to fluoroquinolones: a comparative randomized study
- Authors: Rafal'skiy VV1, Malev IV1, Derevitskiy AV1, Kozlov SN1, Galkin VV1, Rafalsky VV1, Malev IV1, Derevitsky AV1, Kozlov SN1, Galkin VV1
-
Affiliations:
- Issue: No 3 (2009)
- Pages: 18-22
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/277373
- ID: 277373
Cite item
Full Text
Abstract
About the authors
V V Rafal'skiy
I V Malev
A V Derevitskiy
S N Kozlov
V V Galkin
V V Rafalsky
I V Malev
A V Derevitsky
S N Kozlov
V V Galkin
References
- Wagenlehner F. M., Weidner W., Naber K. G. Antibiotics in urology: new essentials. Urol. Clin. N. Am. 2008; 35 (1): 69-79.
- Naber K. G. Treatment options for acute uncomplicated cystitis in adults. J. Antimicrob. Chemother. 2000; 46 (suppl. 1): 23-27.
- Rafalskiy V., Khodnevich L. Prevalence and risk factors of uncomplicated UTI: multicentre study sonar. Eur. Urol. Suppl. 2008; 3 (3): 267.
- Hillier S., Roberts Z., Dunstan F. et al. Prior antibiotics and risk of antibiotic-resistant community-acquired urinary tract infection: case-control study. J. Antimicrob. Chemother. 2007; 60 (1): 92-99.
- Killgore K. M., March K. L., Guglielmo B. J. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann. Pharmacother. 2004; 38 (7): 1148-1152.
- Miller L. G., Mehrotra R., Tang A. W. Does in vitro fluoroquinolone resistance predict clinical failure in urinary tract infections? Int. J. Antimicrob. Agents 2007; 29 (5): 605-607.
- Warren J. W., Abrutyn E., Hebel J. R. t al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin. Infect. Dis. 1999; 29 (4): 745-758.
- Naber K., Bjerklund-Johansen T., Bishop M. EAU guidelines for the management of urinary and male genital tract infections. 2006.
- Raz R., Chazan B., Kennes Y. et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with a high prevalence of TMP-SMX-resistant uropathogens. Clin. Infect. Dis. 2002; 34 (9): 1165-1169.
- Talan D. A., Stamm W. E., Hooton T. M. et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. J. A. M. A. 2000; 283 (12): 1583-1590.
- Gupta K., Stamm W. E. Outcomes associated with trimethoprim/sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI. Int. J. Antimicrob. Agents 2002; 19 (6): 554-556.
- Рафальский В. В., Ходневич Л. В. Влияние резистентности возбудителей инфекций мочевыводящих путей на исходы антибактериальной терапии. Урология 2008; 4: 3-9.
- Grude N., Potaturkina-Nesterova N. I., Jenkins A. et al. A comparison of phylogenetic group, virulence factors and antibiotic resistance in Russian an Norwegian isolates of Escherichia coli from urinary tract infection. Clin. Microbiol. Infect. 2007; 13 (2): 208-211.
- Рафальский В. В., Страчунский Л. С., Бабкин П. А. и др. Резистентность возбудителей неосложненных инфекций мочевых путей в России. Урология 2006; 5: 34-37.
- Рафальский В. В., Рохликов И. М., Страчунский Л. С. Клинико-микробиологическая характеристика внебольничных инфекций мочевых путей в Москве. Урология 2007; 5: 18-23.